Pilot evaluation of aprepitant for the treatment of hot flashes.
Pilot evaluation of aprepitant for the treatment of hot flashes.
复制标题
DOI：
10.3816/sct.2006.n.022
复制
发表时间：
2006-07-01
期刊：
影响因子：
--
通讯作者：
Loprinzi, Charles L
中科院分区：
文献类型：
--
作者：
Bardia, Aditya;Thompson, Susan;Loprinzi, Charles L
背景：潮热是绝经后妇女发病的主要原因，包括许多乳腺癌幸存者。激素疗法可以减少潮热，但由于毒性问题，它并没有像以前那样被广泛使用。各种新的中枢作用剂也被证明可以减少潮热。Aprepitan是一种神经激肽-1受体拮抗剂，是一种中枢活性药物，可能具有减少潮热的能力。本初步试验的目的是评估阿瑞匹坦治疗该患者人群潮热的潜在疗效和安全性。患者和方法：纳入25名绝经后妇女，年龄>/= 45岁，经历令人烦恼的潮热（每周>/= 14次）>/= 1个月。在基线周内，获得了一般人口统计学特征以及潮热和生活质量数据。在第二周开始时，患者每天给予阿瑞匹坦80 mg，持续4周。结果：阿瑞匹坦治疗4周后（n = 21），平均潮热评分（频率乘以平均严重程度）降低17%，平均潮热频率降低15%（与基线第1周相比）。从第1周至第5周，任何患者报告的副作用或生活质量均无统计学显著差异。结论：在本试验中，阿瑞匹坦减少的潮热少于预期的减少20%-25%，这是安慰剂经常出现的情况。因此，阿瑞匹坦似乎不是治疗潮热的有效方法。这项研究表明，神经激肽受体在介导潮热中不起主要作用。
BACKGROUND: Hot flashes are a major cause of morbidity among postmenopausal women, including many survivors of breast cancer. Hormone therapy decreases hot flashes but is not used as much as is has been because of toxicity concerns. Various new centrally acting agents have also been shown to decrease hot flashes. Aprepitan, a neurokinin-1 receptor antagonist, is a centrally active agent that might have the ability to decrease hot flashes. The objective of this pilot trial was to assess the potential efficacy and safety of aprepitant for the treatment of hot flashes in this patient population.PATIENTS AND METHODS: Twenty-five postmenopausal women, aged >/= 45 years, who were experiencing bothersome hot flashes (>/= 14 times per week) for >/= 1 month, were included. During the baseline week, general demographic characteristics and hot flash and quality of life data were obtained. At the beginning of the second week, patients were given aprepitant 80 mg per day for 4 weeks. Information about hot flashes, quality of life, and toxicity was collected during these 4 weeks and compared with week 1.RESULTS: After treatment with aprepitant for 4 weeks (n = 21), mean hot flash scores (frequency times mean severity) were reduced by 17%, and mean hot flash frequencies were decreased by 15% (from the baseline week 1). There were no statistically significant differences from week 1 to week 5 for any of the patient-reported side effects or quality of life.CONCLUSION: The decrease of hot flashes seen with aprepitant in this trial is less than what would be expected from the 20%-25% decrease often seen with a placebo. Thus, aprepitant does not appear to be an effective treatment for hot flashes. This study suggests that neurokinin receptors do not play a major role in mediating hot flashes.